COVID-19 in a patient with neuroendocrine pancreatic cancer – Case Report

Ewa Stępień1,A-D, Małgorzata Polz-Dacewicz1,A-F, Anna Świtalska2,B-D, Maria Malm3,B-C

1 Department of Virology with SARS Laboratory, Medical University, Lublin, Poland
2 Masovian Specialist Hospital, Radom, Poland
3 Department of Medical Informatics and Statistics with E-learning Lab, Medical University, Lublin, Poland

INTRODUCTION

Coronaviruses are a group of important human and animal pathogens that cause diseases. In November 2019, in the city of Wuhan, Hubei Province, China, cases of pneumonia occurred. The novel coronavirus was identified as the cause of the cluster of pneumonia cases. The virus spread rapidly, resulting in an epidemic throughout China, followed by a global pandemic. The identified coronavirus has been named the 2019 novel coronavirus (2019-nCoV). This severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appears to be a new human pathogen. The World Health Organization (WHO) defined the disease as ‘COVID-19’ in February 2020 [1–4].

The Chinese Center for Disease Control and Prevention published a report concerning 72,314 cases of COVID-19 in which 81% of cases were classified as mild (no pneumonia or mild pneumonia), 14% as severe, and 5% as critical [5].

The SARS-CoV-2 virus continues to evolve and, as with other viruses, its variants appear. The variant known as Alpha or B.1.1.7 or 20I/501Y.V1 was first detected in the UK (December 2020) [6–9]. The variant identified in the UK had a higher reproduction rate compared to previous circulating COVID-19 variants. The new variant was also associated with higher disease severity and increased hospitalization and mortality. This variant was detected in almost all countries of the world and rapidly spread globally.

On 1 November 2020, the patient developed cold symptoms (cough, headache, muscle and joint pain, anxiety and tachycardia). Nasopharyngeal swabs were taken for SARS-CoV-2. The nasopharyngeal sample was previously extracted using the Acid Extraction Kit, and tested for SARS-CoV-2 at the SARS-CoV-2 Laboratory of the Medical University in Lublin, Poland. The reaction system was used to detect SARS-CoV-2 viral RNA (Primerdesign Ltd, School Lane, Chandler’s Ford, UK). Reaction system Peptide hormones, including insulin, gastrin, glucagon, and vasoactive intestinal peptide (VIP), can be secreted by these tumours, resulting in multiple clinical syndromes. The risk of viral infections can be increased due to systemic oncological treatment with somatostatin analogues (SSAs) and intensive chemotherapy.

CASE REPORT

The 71-year-old male, a smoker and occasional drinker, was diagnosed in 2014 with a locally invasive pancreatic cancer, NEN Stage T3N1M1, R1. Anticancer therapy: Somatostatin analogues. Complete recovery was achieved without short-term sequelae, and systemic oncological therapy was discontinued.

Peptide hormones, including insulin, gastrin, glucagon, and vasoactive intestinal peptide (VIP), can be secreted by these tumours, resulting in multiple clinical syndromes. The risk of viral infections can be increased due to systemic oncological treatment with somatostatin analogues (SSAs) and intensive chemotherapy.

The nasopharyngeal swabs were positive for SARS-CoV-2. The patient was isolated and treated with antibiotics and antivirals. The patient made a complete recovery without any sequelae. The nasopharyngeal swab was positive for SARS-CoV-2 viral RNA (Primerdesign Ltd, School Lane, Chandler’s Ford, UK). Reaction system Peptide hormones, including insulin, gastrin, glucagon, and vasoactive intestinal peptide (VIP), can be secreted by these tumours, resulting in multiple clinical syndromes. The risk of viral infections can be increased due to systemic oncological treatment with somatostatin analogues (SSAs) and intensive chemotherapy.

This case report describes an NET patient with SARS-CoV-2 infection who completely recovered without sequelae.

The research was approved by the Medical University of Lublin Ethics Committee and by GCP (Good Clinical Practice) regulations (No. KE-0254/295/2019, 26 September 2019). Written informed consent was obtained from the patient.

Address for correspondence: Ewa Stępień, Department of Virology with SARS Laboratory, Medical University, Lublin, Poland
E-mail: ewakliszczewska@umlub.pl

Received: 02.03.2022; accepted: 25.03.2022; first published: 04.04.2022

The 71-year-old male, a smoker and occasional drinker, was diagnosed in 2014 with a locally invasive pancreatic cancer, NEN Stage T3N1M1, R1. Anticancer therapy: Somatostatin analogues.
and amplification conditions were performed according to the manufacturer’s specifications. The result was considered positive when the cycle threshold (Ct) value of the viral gene was 38 or less, and negative when it was greater than 38. Coronavirus (COVID-19) CE IVD genesig® kit detects 0.58 copies/μl of SARS-CoV-2 viral RNA with confidence ≥95%.

Samples were collected every week – on 2, 9, 16, 23 and 30 November. The viral load decreased in each subsequent test (Fig. 1). According to analytical sensitivity, in an analysis of the infection cycle threshold (Ct) over time, it was found that the mean viral load substantially decreased: 106 copies/mL – 2.11.2021; 104 copies/mL – 9.11.2021; 102 copies/mL – 16.11.2021; 10 copies/mL – 30.11.2021 (Fig. 2). On 6 December, the test was negative.

The high viral load in the first test may suggest that infected individuals can be infectious before they become symptomatic. The viral load early after onset was high (>1 × 106 copies per mL).

- **A)** Ct value
- **B)** Viral load in log10 copies/mL

![Figure 1. Viral dynamics of SARS-CoV-2 in a NET patient. A) Relative quantification of viral load – Ct value; B) Viral load in log10 copies/mL](image)

Genotyping was performed by real-time PCR using commercially available test SARS-CoV-2 (20I/501Y.V1, Primerdesign Ltd.) Variant UK was detected.

Antibiotic (Zinnat), steroid (Budesonide), anticoagulant (Clexane) and SCiG (subcutaneous immunoglobulin) were used in the treatment of COVID-19. The patient was vaccinated with the Pfizer vaccine 6 months later. The serum sample was tested for antibodies against SARS-CoV-2 using Microblot-Array COVID-19 IgG (TestLine Clinical Diagnostics Ltd. Brno, Czech Republic – CoVMA96). The test was performed according to the manufacturer’s instructions. Immunogenicity results are reported as an international standard unit (IU/mL). After 2 doses of vaccine, the following antibodies were detected: NP 240 IU/mL, RBD 250 IU/mL, S2 – negative. Six months later, the patient was vaccinated with a booster dose. One month later, in the serum were detected: NP 266 IU/mL, RBD 956 IU/mL, S2 – negative.

**DISCUSSION**

SARS-CoV-2 infection can have a significant impact on cancer diagnosis, prognosis, and therapeutic effects. A worse trend among cancer COVID-19 patients is shown by some studies, whereas other studies point out that the amount of SARS-CoV-2 infection and severe cases in cancer patients does not differ significantly from the general population. Liang et al. [11] proved that patients with cancer were at higher risk of SARS-CoV-2 infection, and also showed an increased risk of severe clinical events in oncology patients (admission to the intensive care unit, invasive ventilation, or death) than those non-oncological.

The frequency of different types of cancer is still unknown in COVID-19 patients. Patients with lung cancer and colorectal cancer are more susceptible to infection with the SARS-CoV-2 virus compared to patients with other types of cancers. Amongst the patients with cancers infected by the SARS-CoV-2 virus, the percentage of patients with different types of cancers were: with lung cancer – 24.7 %, colorectal cancer – 20.5 %, breast cancer – 13.0 %, oesophageal cancer – 7.6 %, bladder cancer – 7.3 %, pancreatic cancer – 6.1 % and cervical cancer – 6.0 %. [14].

A group of 105 cancer patients with COVID-19 participated in a multi-centre retrospective study. This study showed that there was a relatively high risk of severe symptoms of 66.6% and 34.29% in patients with haematological malignancies and metastatic solid tumours, respectively. [15]. A retrospective study showed that for oncology patients with COVID-19, the most common symptoms were fever, dry cough, and fatigue. [16]. In the current case report, the patient did not have a fever. During the course of the disease, the morphological parameters decreased. After the month, the values of these parameters were similar to those before COVID-19.

There are other complications, besides respiratory symptoms, which can develop in oncology patients with COVID-19: acute respiratory distress syndrome (ARDS) (28.6%), followed by pulmonary embolism (7.1%), septic shock (3.6%), and acute myocardial infarction (AMI) (3.6%). They are the most common complications and cause of death in these patients [17,18]. The described patient recovered without complications. After 3 months, in serum samples of infected patients antibodies were detected against SARS-CoV-2 (qualitative test). Mara et al. [19] indicated that the prevalence of SARS-CoV-2 specific IgG antibody does not differ between cancer patients and healthy subjects.

The observations in this case report are similar to those described by Fazio et al. [20] who conducted a worldwide collection of data through an international database to characterise the clinical course of patients with NETs infected by the virus SARS-CoV-2. Their analysis shows that most patients with NET and COVID-19 infection presented a relatively mild illness, with the most frequent symptoms being fever and cough. Some patients were asymptomatic, one-third of the patients had pneumonia, and antibiotics were the most common medical therapy. Moreover, most patients did not require a change in their anti-cancer therapy.

**CONCLUSION**

COVID-19 in the reported NET patient was relatively mild and did not require intensive care. The patient recovered.
without any short-term sequelae. There was no need to stop systemic oncological therapy.

REFERENCES

1. Centers for Disease Control and Prevention. 2019 Novel coronavirus, Wuhan, China. Information for Healthcare Professionals. https://www.cdc.gov/coronavirus/2019-ncov/hcp/index.html (access: 2021.09.08).

2. World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance (access:2021.09.05).

3. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020; 5: 536. https://doi.org/10.1038/s41564-020-0695-z

4. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727–733. https://doi.org/10.1056/NEJMoa2001017

5. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13): 1239–1242. https://doi.org/10.1001/jama.2020.2648

6. European Centre for Disease Prevention and Control. Rapid increase of a SARS-CoV-2 variant with multiple spike protein mutations observed in the United Kingdom, December 2020. https://www.ecdc.europa.eu/sites/default/files/documents/SARS-CoV-2-variant-multiple-spike-protein-mutations-United-Kingdom.pdf (access:2020.12.21).

7. Wise J. Covid-19: New coronavirus variant is identified in UK. BMJ. 2020; 371: m4857. https://doi.org/10.1136/bmj.m4857

8. Tang JW, Tambyah PA, Hui DS. Emergence of a new SARS-CoV-2 variant in the UK. J Infect. 2021; 82(4): e27-e28. https://doi.org/10.1016/j.jinf.2020.12.024

9. Davies NG, Abbott S, Barnard CR, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021; 372(6538): eabg3055. https://doi.org/10.1126/science.abg3055

10. Desai A, Sachdeva S, Parekh T, et al. COVID-19 and Cancer: Lessons From a Pooled Meta-Analysis. JCO Glob Oncol. 2020; 6: 557–559. https://doi.org/10.1200/GO.20.00097

11. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21: 335–337. https://doi.org/10.1016/S1470-2045(20)30096-6

12. Zhang J, Dong X, Cao YY, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020; 75(7): 1730–1741. https://doi.org/10.1111/all.14238

13. Hallet J, Law CHL, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015; 121: 589–597. https://doi.org/10.1002/cncr.29099

14. Wang B, Huang Y. Which type of cancer patients are more susceptible to the SARS-COX-2: Evidence from a meta-analysis and bioinformatics analysis. Crit Rev Oncol Hematol. 2020; 153: 103032. https://doi.org/10.1016/j.critrevonc.2020.103032.

15. Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020; 10(6): 783–791. https://doi.org/10.1158/2159-8290.CD-20-0422

16. Zhang L, Zhu F, Xie L, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020; 31(7): 99–901. https://doi.org/10.1016/j.annonc.2020.03.296

17. Yang F, Shi S, Zhu J, et al. Clinical characteristics and outcomes of cancer patients With COVID-19. J Med Virol. 2020; 92(10): 2067–2073. https://doi.org/10.1002/jmv.25972

18. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

19. Marr A, Generali D, Zagami P, et al. Serocconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. Ann Oncol. 2021; 32(1): 113–119. https://doi.org/10.1016/j.annonc.2020.10.473

20. Fazio N, Gervaso L, Halfdanarson TR, et al. Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study. Eur J Cancer. 2021; 154: 246–252. https://doi.org/10.1016/j.ejca.2021.06.029